STAAR’s results show a story about timing, cash discipline, and what happens when reported growth finally lines up with ...

STAAR Surgical's Q4 results were severely impacted by lower demand and high inventory levels in China. Global growth ex-China was 17% in Q4 and is expected to remain strong at 12% for FY25, with US ...

STAA is a wonderful business selling at a fair price. STAA's business model is straightforward and the CEO does not have to be a genius to run it so long as he follows the playbook that Caren Mason ...